Skip to content

Carrier

Aetna

CVS Health · Drug benefit: CVS Caremark · 6 documents cited · Read September 2026

Says outright that on plans which exclude weight-loss drugs, its clinical criteria do not apply and the claim is denied on the exclusion.

Denise Ramirez, Coverage Editor · Who writes this

Aetna states the thing other carriers imply. Its own medical policy on weight reduction says that many of its benefit plans specifically exclude weight-loss drugs, and then says what follows: on those plans the medical necessity criteria below do not apply, and claims for weight-loss drugs will be denied on the exclusion.

That sentence is worth more to a reader than any criteria table, because it tells you which argument is available to you. If the exclusion is what denied you, the clinical file is not the problem and sending more of it will not change the answer. It also tells you where to look: Aetna says the exclusion can sit under the pharmacy benefit, under the medical benefit, or both, so there are two documents to check rather than one.

Underneath that, Aetna publishes two different adult BMI floors for the same drugs. Its main 2026 policy sets 35 and adds a requirement most readers will not expect: six months in a comprehensive weight management program before drug therapy starts. A second policy, written for certain states, sets 40 — or 35 with a comorbidity — and never says which states it means.

We could not find anything public that tells you which of those applies to you, and Aetna's member-facing complaints and appeals page publishes no filing deadline at all. Both of those gaps are recorded below rather than filled in.

Read the exclusion sentence first

Aetna's Clinical Policy Bulletin on weight reduction carries a note above its criteria saying that many of its plans specifically exclude coverage of weight-reduction medications under the pharmacy benefit, the health benefit, or both. The sentence that follows is the one that matters: on plans with that exclusion, the criteria in the bulletin do not apply, and claims are denied on the exclusion.

A carrier rarely writes down the point at which its own rules stop governing. This one does, and it means a denial letter citing an exclusion and a denial letter citing medical necessity are not variations on a theme. They are different decisions made under different documents.

The member-facing version of the same fact is softer. Aetna's commercial clinical program summary tells members only that their plan may not cover certain drugs for conditions such as infertility, erectile dysfunction and weight loss, and points them at their plan documents.

Two BMI floors, and one policy that will not name its states

Aetna's 2026 policy for the GLP-1 and GIP-GLP-1 weight-loss drugs is titled for a BMI of 35, and that is the adult threshold it sets. It also requires something the threshold does not hint at: six months of participation in a comprehensive weight management program with behavioral modification, reduced-calorie diet, increased physical activity and continuing follow-up, before drug therapy.

A second policy still in force sets a different floor. It admits adults at a BMI of 40, or 35 with a comorbid condition, and it is titled for specific states. We searched its whole text for the name of any state and found none — the only two state names in the document are a drug maker's address and a database vendor's, both in the reference list.

So Aetna publishes a policy that applies to some readers and not others, and publishes nothing that tells a reader which group they are in. That is not a criticism of the criteria. It is a limit on what you can learn from reading them.

On one commercial plan, Zepbound is excluded and Wegovy is the alternative

Aetna's 2026 formulary exclusions list for the Advanced Control Plan, dated July 2026, is a table of drugs that plan does not cover next to the ones it prefers instead. Three weight-management drugs are in the excluded column: Zepbound, Contrave and Xenical. The preferred options printed beside each of them are the same four: liraglutide, orlistat, Qsymia and Wegovy.

That is a specific and checkable fact about one plan design, and it inverts what a lot of readers assume. On this plan the newer tirzepatide product is the one shut out, and semaglutide is the route the plan wants you on. Saxenda and Foundayo appear nowhere on the exclusions list at all.

It applies to the Advanced Control Plan and to nothing else by itself. Aetna runs several formularies, and the exclusions list you need is the one named in your own plan materials.

The carve-out worth knowing about

Aetna's 2026 weight-loss policy includes a note that changes where two Zepbound presentations are obtained. It says the drugs it lists include all forms and strengths except Zepbound vials and Zepbound KwikPens, which are covered under the LillyDirect manufacturer program.

In plain terms, the policy is telling prescribers that two specific presentations are routed outside the pharmacy benefit it governs. If a pharmacy tells you a Zepbound vial is not covered, that is consistent with what this policy says, and it does not mean the same thing as the drug being excluded from your plan.

What Aetna publishes about deadlines, which is less than you would expect

Aetna's page for health care professionals states a 180-day filing standard for disputes and appeals and says there are state exceptions to it, which apply to members covered under fully insured plans. It does not list the exceptions on that page.

Its member-facing page on complaints, grievances and appeals publishes no filing window at all. We read the whole page — around 40,000 characters of text, with the word "appeal" on it eighteen times — and the word "day" does not appear once. It routes members to an online form, a printable form, the Medicare process, and their state insurance office.

So the number a member needs is on the notice they were sent and in their plan document, not on Aetna's website. This page does not supply one in its place.

Every claim above, with the document behind it

These are the policies we opened and the month we opened them. Each one carries its own policy number and effective date on its face, and those are printed here as the document shows them.

Aetna states when its own criteria stop applying. Its weight reduction policy notes that "Many Aetna benefit plans specifically exclude coverage of weight reduction medications under the pharmacy benefit and/or under the health benefits plan," and continues: "The medical necessity criteria set forth below do not apply to health plans that specifically exclude services and supplies for or related to treatment of obesity or for diet or weight control. Under these plans, claims for weight loss drugs will be denied based on this exclusion." The policy's history records a last review of 03/10/2026.

Aetna, Medical Clinical Policy Bulletin 0039, "Weight Reduction Programs and Devices", effective February 2000 · source

Aetna's current weight-loss GLP-1 policy sets an adult floor of 35 and requires half a year of program participation before the drug. Authorization may be granted where "The patient has a baseline body mass index (BMI) greater than or equal to 35 kg/m2" and "The patient has participated in a comprehensive weight management program that encourages behavioral modification, reduced-calorie diet, AND increased physical activity with continuing follow-up for at least 6 months prior to using drug therapy."

Aetna, Pharmacy Clinical Policy Bulletin, "Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8" · source

A second Aetna policy sets a different floor and will not say where it applies. Titled "Antiobesity Agents Aetna ONLY for Specific States PA with Limit 5098-C UDR 08-2023 v6", it grants authorization where the patient has "a current body mass index (BMI) of greater than or equal to 40 kg/m2", or a BMI of at least 35 with a comorbid condition. We searched all 25,687 characters of the document for the name of every US state; the only two that appear are Indianapolis and Ann Arbor, Michigan, in the reference list. The words "obesity" and "BMI" appear 22 and 27 times in the same search, so the search was working.

Aetna, Pharmacy Clinical Policy Bulletin, "Antiobesity Agents Aetna ONLY for Specific States PA with Limit 5098-C UDR 08-2023 v6" · source

On one Aetna commercial plan, Zepbound is excluded and Wegovy is a preferred alternative to it. The 2026 Formulary Exclusions Drug List for the Advanced Control Plan, headed "Drugs not covered — and their covered alternatives", carries three weight-management entries in its excluded column — ZEPBOUND, CONTRAVE and XENICAL — each printed against the same preferred options: "liraglutide, orlistat, QSYMIA, WEGOVY". Saxenda and Foundayo do not appear on the list at all.

Aetna, "2026 Formulary Exclusions Drug List — Advanced Control Plan", effective July 2026 · source

Two Zepbound presentations are routed outside the benefit this policy governs. The policy's own note reads: the listed drugs include all forms and strengths "except Zepbound vials and Zepbound Kwikpens, which are covered under the LillyDirect manufacturer program."

Aetna, Pharmacy Clinical Policy Bulletin, "Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8" · source

The member-facing warning is much softer than the policy language, and it names who runs the drug benefit. Aetna's commercial clinical program summary tells members: "Your plan may not cover certain drugs to treat conditions such as infertility, erectile dysfunction and weight loss." The same document states that "Pharmacy benefits are administered by an affiliated pharmacy benefit manager, CVS Caremark" and that "Aetna® is part of the CVS Health® family of companies."

Aetna, "2026 Aetna Commercial Clinical Program Summary", effective 2026 · source

Aetna publishes a filing standard to providers and no filing window to members. Its disputes and appeals page for health care professionals says: "We also list exceptions to our 180-day filing standard. Exceptions apply to members covered under fully insured plans." Its member page on complaints, grievances and appeals carries no deadline — we read all 40,288 characters of its text, on which the word "appeal" appears 18 times and the word "day" appears zero times.

Aetna, "Disputes and appeals" (health care professionals) and "Complaints, grievances and appeals" (members) · source

What these documents cannot tell you

Everything above is what Aetna publishes. None of it establishes what your own plan does, and the gap between those two things is wider than a carrier policy makes it look.

  • Nothing Aetna publishes tells you which of its policies governs you. Two adult BMI floors are in force, one of them in a policy titled for states it never names, and no public document maps a member to either.
  • The exclusions list quoted above is for the Advanced Control Plan. Aetna maintains several formularies and several exclusion lists; the one that binds you is the one named in your own plan materials, and it may not be this one.
  • Whether the exclusion applies to you is a plan question, not a policy question. Aetna's own bulletin says the exclusion can sit under the pharmacy benefit, the health benefit, or both, which means checking one of them is not checking.
  • A self-funded employer plan may adopt different rules. The name on the card does not settle whose criteria govern you or whether state insurance law reaches the plan.
  • None of this is legal or medical advice, and this page does not predict how an appeal will come out. Your plan document and the notice you received govern your case.

Where this comes from

  1. Aetna, Medical Clinical Policy Bulletin 0039, "Weight Reduction Programs and Devices", effective February 2000 — www.aetna.com/cpb/medical/data/1_99/0039.html
  2. Aetna, Pharmacy Clinical Policy Bulletin, "Weight Loss (BMI 35) GIP-GLP-1, GLP-1 Agonists PA with Limit 6450-C P08-2025 v8" — www.aetna.com/products/rxnonmedicare/data/2026/Weight_Loss_(BMI%2035)_GI
  3. Aetna, Pharmacy Clinical Policy Bulletin, "Antiobesity Agents Aetna ONLY for Specific States PA with Limit 5098-C UDR 08-2023 v6" — www.aetna.com/products/rxnonmedicare/data/2025/Antiobesity_Agents_Aetna_
  4. Aetna, "2026 Formulary Exclusions Drug List — Advanced Control Plan", effective July 2026 — www.aetna.com/content/dam/aetna/pdfs/aetnacom/individuals-families-healt
  5. Aetna, "2026 Aetna Commercial Clinical Program Summary", effective 2026 — www.aetna.com/content/dam/aetna/pdfs/aetnacom/individuals-families-healt
  6. Aetna, "Disputes and appeals" (health care professionals) and "Complaints, grievances and appeals" (members) — www.aetna.com/health-care-professionals/disputes-appeals.html

Where to go next

American GLP is not a law firm, an insurer, a government office or a clinician, and nothing here is legal or medical advice. This page describes what Aetna publishes. It is not affiliated with CVS Health, and your own plan documents and your own notice govern your case. Policies carry effective dates and change — read the sources before you act.